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ABSTRACT
Objective: The aim of this study was to evaluate the performance of maize starch as a multifunctional 
excipient in metronidazole tablet formulation.
Methods: Metronidazole tablets were prepared by wet granulation containing maize starch as diluent 
(40 %), disintegrant (10 %), and binder (5 %) and compared with a reference formulation containing 
lactose as diluent (40 %), maize starch as disintegrant (10 %) and acacia as binder (5 %). The granules 
were analysed for particle size, flow properties, compressibility and moisture content. Tablets weighing 
500 mg were compressed for both formulations on a Single Punch Tablet Press using a 12 mm flat-faced 
punches at 57.5 MPa. The tablets were kept for 24 h to allow for elastic recovery and evaluated for 
weight and content uniformity, thickness, crushing strength, friability, disintegration time and in vitro 
drug release.
Results: The granule properties revealed differences in mean granule size, angle of repose, bulk and 
tapped densities for both formulations. Batch I tablets gave rise to better tableting properties compared 
to batch II tablets.
Conclusion: This study confirms the suitability of maize starch as a multifunctional excipient in tablet 
formulation.
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RESUMEN
Objetivo: El objetivo de este estudio fue evaluar el rendimiento del almidón de maíz como excipiente 
multifuncional en la formulación de comprimidos de metronidazol.
Métodos: Metronidazol Tabletas En Honorario preparado por granulación húmeda que contiene almi-
dón de maíz como diluyente (40%), desintegrante (10%) y aglutinante (5%) y en comparación con una 
formulación de referencia que contiene lactosa como diluyente (40%), almidón de maíz como desinte-
grante (10%) y Acacia como aglutinante (5%). Los gránulos se analizaron para el tamaño de partícula, 
propiedades de flujo, compresibilidad y contenido de humedad. Las tabletas con un peso de 500 mg 
fueron comprimidas para ambas formulaciones en una simple Punch Tablet Press usando un punzón 
de 12 mm de cara plana en 57,5 MPa. Los comprimidos se mantuvieron durante 24 h para permitir la 
recuperación elástica y evaluar el peso y el contenido uniformidad, espesor, resistencia a la trituración, 
friabilidad, tiempo de desintegración y in vitro liberación de drogas.
Resultados: Las propiedades del gránulo revelaron diferencias en el tamaño medio del gránulo, el án-
gulo de reposo, las densidades a granel y roscado para ambas formulaciones. Los comprimidos de Batch 
I dieron lugar a mejores propiedades de comprimidos en comparación con los comprimidos de lote II.
Conclusión: Este estudio confirma la idoneidad del almidón de maíz como excipiente multifuncional en 
la formulación de comprimidos.
Palabras clave: Almidón de maíz; excipiente multifuncional; gránulos; comprimidos
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INTRODUCTION
Tablets are prepared by compressing unit volumes of gran-
ules or a powder blend of the active drug and excipients. 
Excipients are added in optimal quantities to a formula-
tion to facilitate the tableting process and ensure that the 
desired quality of the tablet is achieved. For this reason, 
excipients have been regarded as functional components 
of a formulation(1) because they contribute significantly to 
the processing, stability, safety, bioavailability and perfor-
mance of the dosage form containing the drug. Among the 
many examples available to the pharmaceutical industry, 
starches constitute a major source of excipients in tablet 
formulation. They have been drawn from a wide variety 
of sources including cereal and tuber crops and have been 
used extensively as diluents, disintegrants, binders and gl-
idants in tablet formulation(2,3). Due to their versatility and 
robust nature, starches can perform several functions in a 
formulation depending on its mode of incorporation. As a 
powder, starches can be incorporated as a bulking agent(4), 
intra- or extragranular disintegrant(5,6) and glidant(4) while 
as a paste, starches have been utilized as binders(7-9) in tablet 
formulation with excellent results. Starches, therefore, have 
the potential for multifunctional application in tablet for-
mulation. In the present study, maize starch was evaluated 
as a multifunctional excipient in the formulation of met-
ronidazole tablets by wet granulation. Maize starch was 
incorporated concurrently as a diluent, disintegrant and 
binder in metronidazole tablet formulation and compared 
with a reference formulation containing lactose as diluent, 
maize starch as disintegrant and acacia as binder using the 
same concentrations.
MATERIALS AND METHODS
Materials
Metronidazole (Central Drug House (P) Ltd. New Delhi), 
Maize Starch (Burgoyne Burbidge & Co. (India), Mumbai), 
Lactose (DFE Pharma, Germany), Acacia (Kerry Ingredi-
ents and flavours Ltd, Ireland), Colloidal silicon dioxide 
(Evonik Industries, Germany), Sodium Stearyl Fumarate 
(JRS Pharma, Germany). All other materials used were of 
pharmaceutical grade.
Methods
Preparation of metronidazole granules and tablets
Metronidazole granules were prepared by mixing met-
ronidazole powder (30 g), lactose (filler, 30 g) and maize 
starch (disintegrant, 7.5 g) together in a mortar and pestle 
for 5 mins. A binder solution containing acacia (3.75 g) was 
prepared and incorporated to mass the powder mix. The 
massed powder was screened by passing through a sieve 
(1.6 mm). The granules formed were dried in the oven at 
40 °C for 10 mins. Subsequently, the granules were passed 
through sieve (0.8 mm) and dried completely in the oven 
at 40 °C for 2 h. The entire process of granulation was re-
peated using maize starch as filler, binder and disintegrant 
in the same proportions as above. The granules were char-
acterized for particle size, angle of repose, bulk density, 
tapped density, Carr’s index, Hausner’s ratio and moisture 
content according to reference methods. The granules were 
then lubricated by mixing with colloidal silicon dioxide 
and sodium stearyl fumarate for 5 mins. The lubricated 
granules were fed automatically into die cavity measuring 
12 mm from the hopper and compressed into tablets weigh-
ing 500 mg at a compression pressure of 57.5 MPa on a Sin-
gle Punch Tablet Press (Type EKO, Erweka, Apparatebau, 
Germany). Tablets were ejected from the die and kept for 24 
h to allow for elastic recovery prior to evaluation of tablet 
properties. The formula for preparing granules and tablet is 
given in Table 1 below.
Table 1. Formula for preparing metronidazole granules and tablets for batches I & II formulations (batch size=150 tablets)
Ingredients I II
Metronidazole (40 %) 30 30
Lactose (40 %) - 30
Maize starch (40 %) 30 -
Maize starch (10 %) 7.5 7.5
Maize starch (5 %) 3.75 -
Acacia (5 %) - 3.75
Colloidal silicon dioxide (4 %) 3 3
Sodium stearyl fumarate (1 %) 0.75 0.75
Total (g) 75 75
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Particle size analysis
The mean granule size (MGS) for each batch of granules 
was determined using the sieving method(10). Test sieves 
ranging from 1000 µm to < 75 µm (Pan) were arranged in 
descending order. Approximately 20 g sample of the gran-
ules was placed in the top most sieve and allowed to vibrate 
for 10 mins in the Endecott test sieve shaker to allow for 
separation of granules based on their different sizes. The 
quantity of granules retained on each sieve was weighed 
and the mean granule size was calculated using the formu-
la given below.
Optical microscopy
Optical images of the granules examined at 40 x magnifica-
tion were generated using a camera mounted on the micro-
scope. The photomicrographs for all the batches of granules 
were taken and recorded.
Angle of repose
The angle of repose for each batch of granules was meas-
ured using the Pilpel method(11). About 20 g of granules 
was poured through a funnel suspended at a height of 8 
cm onto a flat surface forming a conical heap of powder. 
The dimensions of height and radius were measured and 
computed using the equation given below. A mean of three 
replicates was reported with the standard deviation.
Where h and r are height and radius respectively
Bulk and tapped densities
Bulk (BD) and tapped densities were measured in tripli-
cate for each batch of granules. The volume occupied by 
20 g of granules poured into a 50 mL measuring cylinder 
was recorded as the bulk volume (VB) and the volume ob-
tained after tapping to constant volume was recorded as 
the tapped volume (VT). Bulk and tapped densities were 
calculated using the formula given below.
The parameters of Carr’s Index (CI) and Hausner’s ratio 
(HR) were equally calculated using the bulk and tapped 
densities as shown in Equations 5 & 6 respectively.
Moisture content
The moisture content was obtained by drying to constant 
weight 1 g sample of granules in the oven at 105 . Moisture 
content expressed in percentage was calculated using the 
equation given below,
Tablet evaluation
Tableting parameters were evaluated according to BP spec-
ifications(12).
Uniformity in weight
Twenty (20) tablets from each batch were randomly sam-
pled and their weights determined using an electronic bal-
ance. The mean and standard deviation were computed 
and recorded.
Content uniformity test
The average weight of five tablets powdered was weighed 
out and dissolved in 100 mL of 0.1 N HCl. The mixture 
was filtered and sufficiently diluted with 0.1 N HCl before 
the absorbance value was read off at 277 nm using the UV 
Spectrophotometer. This was carried out for both batches. 
The % drug content was computed using the straight-line 
equation, y = 0.0395x + 0.1314, derived from the calibration 
curve of metronidazole where y is the absorbance and x is 
drug concentration (µg/mL).
Tablet thickness
The thickness of five (5) tablets randomly selected from 
each batch was measured using a digital vernier calliper. 
A mean of five determinations was recorded with standard 
deviation.
Crushing strength (CS) and tensile strength (TS)
The force required to a crush a tablet diametrically was 
measured using a Monsanto hardness tester. A mean of five 
replicates was recorded as the crushing strength for each 
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batch of tablet. Tensile strength was calculated using the 
Fell and Newton(13) equation given below:
Where F, d and t are the crushing strength, diameter and 
thickness respectively.
Friability test (FR)
Tablet friability was determined for each batch of tablets 
using an Erweka Friabilator (TA 20, GmbH, Heusenstamm, 
Germany). The initial weight (Wi) of ten (10) tablets was 
taken, placed in the friabilator and allowed to rotate at 25 
rpm for 4 min. The final weight (Wf) of tablets was taken 
after removal of dust and friability calculated as follows:
Disintegration time (DT)
The time taken for six (6) tablets to disintegrate from each 
batch was assessed using the Disintegration tester (ZT-4, 
Erweka, Heusenstamm, Germany) as described in the Brit-
ish Pharmacopoeia(12). A mean of six determinations was 
recorded for each batch of tablets.
In vitro drug release studies
Tablet dissolution studies was conducted on both batch-
es using the Erweka dissolution apparatus (Type DT6, 
GmbH, Heusenstamm, Germany) under sink conditions. 
Drug release was determined in 900 mL 0.1 N HCl at a 
basket speed of 50 rpm and temperature of 37 ± 0.5°C. A 
tablet was placed carefully in the vessel and at the follow-
ing intervals of 5, 10, 20, 30, 45 and 60 mins respectively, 
5 mL samples were withdrawn and replaced with equal 
volume of 0.1 N HCl after each withdrawal. The samples 
collected were filtered and sufficiently diluted with 0.1 N 
HCl before taking the absorbance readings at 277 nm using 
the UV spectrophotometer (UV – 1800 Spectrophotometer, 
Shimadzu Corporation, USA). The amount of metronida-
zole released (%) was calculated based on the regression 
equation, y = 0.0395x + 0.1314, derived from the calibration 
curve of metronidazole. A mean of three determinations 
was obtained and a graph of amount of drug released (%) 
against time was plotted to establish the dissolution profile 
of both batches of tablets.
RESULTS
Granule Properties
The granule properties of batches I & II formulations are 
presented in Table 2. The mean granule size (MGS) for 
batch I formulation was greater than that of batch II. Eval-
uation of flow parameters revealed that the angle of repose 
for both batches ranged between 32 – 36 º. A higher flow 
rate was obtained for batch I formulation relative to batch 
II formulation.
Table 2. Granule properties of Batches I & II formulations
Parameters Batch I Batch II
Mean granule size 
(µm)
330.46 288.35
Angle of repose(ᶱ) 36.04 ± 1.22 32.17 ± 2.62
Bulk density (g/
mL)
0.41 ± 0.002 0.45 ± 0.00
Tapped density 
(g/mL)
0.49 ± 0.01 0.56 ± 0.00
Flow rate (g/sec) 4.26 ± 0.17 3.71 ± 0.0
Carr’s index (%) 17.47 ± 1.27 19.1 ± 0.0
Hausner’s ratio 1.21± 0.02 1.24 ± 0.0
Moisture content 
(%)
5 7
Bulk and tapped densities of batch I formulation lower in 
comparison to batch II formulation. The values of CI and 
HR computed for batch I formulation were slightly low-
er than those of batch II formulation. Moisture content for 
both formulations did not exceed 7 %. Photomicrographs 
of batches I & II formulations displayed as Figure 1 shows 
that the granules of batch I formulation are bigger in size 
compared to granules of batch II formulation. The granules 
for both formulations appear irregular and spongy-like in 
shape demonstrating a high degree of agglomeration of 
primary powder particles. Overall, granule properties for 
both formulations appear to differ considerably possibly 
due to the composition of the formulation.
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(a) (b)
Figure 1. Photomicrographs of (a) batches I granules & (b) batch II granules
Tablet Properties
Tablet properties of both formulations are summarized in 
Table 3. The mean tablet weight of batches I & II formula-
tions was 498 and 494 mg respectively. Content uniformity 
of batch I tablets was above the limit set for acceptable tab-
lets compared to batch II tablets. Thickness of the tablets 
varied with the batches as batch I tablets recorded a lower 
mean thickness compared to that of batch II. Tablet density 
was slightly higher for batch I tablets compared to batch II 
tablets.
Table 3. Tablet properties of batches I & II formulations
Parameters Batch I Batch II
Mean weight (mg) 498 ± 3.40 494 ± 5.03
Content uniform-
ity (%)
113.35 103.87
Thickness (mm) 4.46 ± 0.01 4.84 ± 0.1
Tablet density (g/
mL)
0.99 ± 0.01 0.87 ± 0.01
Crushing strength 
(N)
42.6 ± 2.1 20 ± 1.7
Tensile strength 
(MPa)
0.5 ± 0.02 0.22 ± 0.02
Friability (%) 1.41 3.63
Disintegration 
time (min)
3.75 ± 0.51 0.22 ± 0.0
The crushing strength of batch I tablets was found to be 
higher compared to that of batch II. This correlated well 
with the friability and disintegration times of tablets as the 
batch of tablets with higher crushing strength produced 
tablets that were less friable and took a longer time to dis-
integrate into granules and primary particles. The drug-re-
lease profile of both formulations illustrated in Figure 2 
shows that more than 80 % of the drug was released in less 
than 5 mins for both formulations.
Figure 2. Drug-release profile of batches I & II tablets
DISCUSSION
The aim of this study was to evaluate the performance of 
maize starch as a multifunctional excipient in the formu-
lation of metronidazole tablets by wet granulation. A mul-
tifunctional excipient is that excipient that can serve two 
or more roles in a formulation(14,15) i.e. diluent, disintegrant 
and binder. Maize starch was utilized as a diluent, disinte-
grant and binder in batch I formulation in comparison to its 
performance as a disintegrant only in batch II formulation. 
Significant differences were observed in the granule prop-
erties of both formulations suggesting that the composition 
of the granules exerted a dominant effect on its properties. 
Mean granule size (MGS) of batch I formulation was great-
er than that of batch II formulation owing to the pasting 
and binding properties of maize starch. In addition, maize 
starch present in large proportions as a multifunctional ex-
cipient in batch I formulation may have contributed to the 
wettability of the powder blend of ingredients leading to a 
greater degree of agglomeration of primary powder par-
ticles during granulation. The swelling property of starch 
attributed to its hydrophilicity is likely to have facilitated 
particle adhesion during granulation leading to granules 
larger in size. The extent of wettability of acacia as a bind-
er in batch II formulation may have influenced its capacity 
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to agglomerate particles during granulation giving rise to 
a MGS relatively lower than that of batch I formulation. 
Assessing the flow properties of the granules showed that 
the flow rate of granules was consistent with the granule 
size as larger particles generally flow faster. Hence batch 
I formulation had a better flow rate compared to batch II 
formulation. Similarly, bulk and tapped densities of batch 
I granules were relatively lower compared to that of batch 
II granules because of lower degree of packing associated 
with larger particle size and this translated to better flow 
rate due to a greater degree of porosity. The granule prop-
erties obtained for batch I formulation translated into better 
tableting properties for the formulation in terms of crush-
ing strength, tensile strength, tablet density and friability. 
The differences observed in the tableting parameters of 
crushing strength and disintegration time of both formu-
lations was statistically significant at p < 0.05. The higher 
crushing and tensile strength values obtained for batch I 
formulation can be attributed to a greater degree of bond-
ing area and bonding strength per unit area occurring dur-
ing compression. It implies therefore that the formulation 
containing maize starch as a multifunctional excipient was 
more compressible and compactable leading to a better 
tabletability of the formulation. This is consistent with the 
findings of Nasipuri(16) and Deshpande and Panya(17) who 
recorded better performances in tableting properties when 
starches from various sources were used as binders in 
comparison to acacia. The poor friability outcome of both 
formulations can be attributed to a higher concentration of 
disintegrant (10 %) used in the formulation compared to 
a binder concentration of 5 %. The relatively longer disin-
tegration time of batch I formulation can be linked to the 
hardness of the tablets. Harder tablets take a longer time to 
disintegrate as it will require more time for the disintegrat-
ing medium to overcome the strength of the bonds formed 
in the tablet. Nevertheless, both formulations passed the 
disintegration test as the disintegration time did not exceed 
15 mins as recommended for immediate release tablets(12). 
The drug-release profile of both formulations did not differ 
significantly even though a significant difference (p < 0.05) 
was observed in their disintegration times. Maximum drug 
release of 100 % was attained at about the same rate and 
time for both formulations. This agrees with the findings of 
Odeku and Akinwande(6)assessed using the disintegration 
and dissolution (t 50 and t 80 - time required for 50% and 
80% of paracetamol to be released that the dissolution rate 
does not necessarily depend on the disintegration time.
CONCLUSION
The application of maize starch as a multifunctional ex-
cipient has been investigated. Better tableting properties 
were obtained with formulations containing maize starch 
as multifunctional excipient compared to when it was used 
only as a disintegrant in batch II formulation. This confirms 
the suitability of maize starch as a multifunctional excipient 
in tablet formulation.
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